State of New Jersey Common Pension Fund D Decreases Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

State of New Jersey Common Pension Fund D lowered its stake in TG Therapeutics, Inc. (NASDAQ:TGTX) by 27.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 82,752 shares of the biopharmaceutical company’s stock after selling 30,931 shares during the period. State of New Jersey Common Pension Fund D owned 0.05% of TG Therapeutics worth $1,936,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. NBC Securities Inc. increased its stake in shares of TG Therapeutics by 58.9% in the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 485 shares during the period. Ashton Thomas Private Wealth LLC acquired a new stake in shares of TG Therapeutics in the second quarter worth $35,000. Blue Trust Inc. increased its stake in shares of TG Therapeutics by 127.3% in the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 849 shares during the period. ORG Wealth Partners LLC acquired a new stake in shares of TG Therapeutics in the third quarter worth $53,000. Finally, DekaBank Deutsche Girozentrale acquired a new stake in shares of TG Therapeutics in the first quarter worth $58,000. Hedge funds and other institutional investors own 58.58% of the company’s stock.

TG Therapeutics Stock Down 4.2 %

TGTX stock opened at $29.54 on Monday. The stock has a market capitalization of $4.60 billion, a P/E ratio of -295.40 and a beta of 2.19. The firm has a 50-day simple moving average of $24.74 and a 200-day simple moving average of $21.16. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. TG Therapeutics, Inc. has a 52 week low of $10.98 and a 52 week high of $36.50.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.01). The business had revenue of $83.90 million for the quarter, compared to analysts’ expectations of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm’s revenue was down 49.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.73 EPS. Equities analysts forecast that TG Therapeutics, Inc. will post 0.17 earnings per share for the current fiscal year.

Insider Buying and Selling at TG Therapeutics

In other news, Director Sagar Lonial sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $30.44, for a total value of $152,200.00. Following the transaction, the director now directly owns 100,195 shares in the company, valued at approximately $3,049,935.80. This represents a 4.75 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 10.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of analysts have recently weighed in on TGTX shares. HC Wainwright increased their price objective on shares of TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. The Goldman Sachs Group raised their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. B. Riley lifted their price objective on shares of TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Finally, TD Cowen started coverage on shares of TG Therapeutics in a report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $37.67.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.